Friday, March 05, 2021 5:22:52 AM
Here's one for you too:
Does VIP function as modulator in regions of the brain associated with anxiety and depression
https://www.nature.com/articles/s41598-020-80873-2
nature scientific reports articles Published: 14 January 2021
Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females
Rozalyn A. Simon, Nawroz Barazanji, Michael P. Jones, Olga Bednarska, Adriane Icenhour, Maria Engström, J. Paul Hamilton, Åsa V. Keita & Susanna Walter
Scientific Reports
volume 11, Article number: 1406 (2021) Cite this article
Abstract
Vasoactive intestinal polypeptide (VIP) is a neuroendocrine peptide distributed throughout the human body, including the CNS, where it is particularly abundant in brain regions associated with anxiety and depression. Based on earlier studies indicating that peripheral VIP may cross through the blood–brain barrier, we hypothesized plasma VIP levels to be associated with symptoms of anxiety and depression, as well as brain volume and resting-state functional connectivity in the amygdala, hippocampus, parahippocampus, and orbitofrontal cortex.
Plasma VIP concentrations and anxiety/depression symptoms were measured in 37 healthy females. Functional and structural magnetic resonance imaging were used to evaluate functional connectivity and brain volume respectively, and their associations with VIP concentrations within brain regions associated with anxiety and depression. Negative correlations were found between VIP levels and symptoms of anxiety (r?=?- 0.44, p?=?0.002) and depression (r?=?- 0.50, p?=?0.001). Functional connectivity demonstrated significant VIP-dependent positive associations between the amygdala seed region with both the right parahippocampus (t(33)?=?3.1, pFDR?=?0.02) and right lateral orbitofrontal cortex (OFC; t(33)?=?2.9, pFDR?=?0.02). Moreover, VIP concentrations were significantly, positively correlated with brain volume in the left amygdala (r?=?0.28, p?=?0.007) and left lateral OFC (r?=?0.29, p?=?0.004).
The present findings highlight a potential role for VIP in the neurobiology of affective symptoms.
Does VIP function as modulator in regions of the brain associated with anxiety and depression
https://www.nature.com/articles/s41598-020-80873-2
nature scientific reports articles Published: 14 January 2021
Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females
Rozalyn A. Simon, Nawroz Barazanji, Michael P. Jones, Olga Bednarska, Adriane Icenhour, Maria Engström, J. Paul Hamilton, Åsa V. Keita & Susanna Walter
Scientific Reports
volume 11, Article number: 1406 (2021) Cite this article
Abstract
Vasoactive intestinal polypeptide (VIP) is a neuroendocrine peptide distributed throughout the human body, including the CNS, where it is particularly abundant in brain regions associated with anxiety and depression. Based on earlier studies indicating that peripheral VIP may cross through the blood–brain barrier, we hypothesized plasma VIP levels to be associated with symptoms of anxiety and depression, as well as brain volume and resting-state functional connectivity in the amygdala, hippocampus, parahippocampus, and orbitofrontal cortex.
Plasma VIP concentrations and anxiety/depression symptoms were measured in 37 healthy females. Functional and structural magnetic resonance imaging were used to evaluate functional connectivity and brain volume respectively, and their associations with VIP concentrations within brain regions associated with anxiety and depression. Negative correlations were found between VIP levels and symptoms of anxiety (r?=?- 0.44, p?=?0.002) and depression (r?=?- 0.50, p?=?0.001). Functional connectivity demonstrated significant VIP-dependent positive associations between the amygdala seed region with both the right parahippocampus (t(33)?=?3.1, pFDR?=?0.02) and right lateral orbitofrontal cortex (OFC; t(33)?=?2.9, pFDR?=?0.02). Moreover, VIP concentrations were significantly, positively correlated with brain volume in the left amygdala (r?=?0.28, p?=?0.007) and left lateral OFC (r?=?0.29, p?=?0.004).
The present findings highlight a potential role for VIP in the neurobiology of affective symptoms.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
